Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609633 | 0.98 | KDM4E (0.44) | KDM4EEPHX1SIGMAR1EPHX2ANPEP | |
| SCHEMBL11058163 | 0.95 | KDM4E (0.47) | KDM4EEPHX1SIGMAR1EPHX2ANPEP | |
| SCHEMBL11054718 | 0.87 | KDM4E (0.50) | KDM4EEPHX1ANPEPERAP2HTT | |
| SCHEMBL18814445 | 0.85 | METAP1 (0.46) | KDM4E | |
| SCHEMBL20016428 | 0.83 | GNAI3 (0.33) | EPHX1 | |
| SCHEMBL22236675 | 0.82 | KDM4E (0.46) | KDM4EEPHX1SIGMAR1EPHX2ANPEP | |
| SCHEMBL7611083 | 0.81 | ALDH1A1 (0.46) | KDM4EEPHX1SIGMAR1EPHX2ANPEP | |
| SCHEMBL9407491 | 0.80 | KDM4E (0.60) | KDM4EEPHX1ANPEPERAP2HTT | |
| SCHEMBL25708221 | 0.79 | ALDH1A1 (0.44) | KDM4EEPHX1SIGMAR1EPHX2ANPEP | |
| SCHEMBL22115045 | 0.79 | S1PR1 (0.34) | EPHX1SIGMAR1EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-4459424-A | SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST | AKZONA INCORPORATED (US) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | KDM4E 2957/4885EPHX1 3460/4885SIGMAR1 2876/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | KDM4E 2957/4885EPHX1 3460/4885SIGMAR1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.